Will Pravachol Follow Zocor On UK Switch Route?
This article was originally published in The Tan Sheet
Executive Summary
Mounting pressure on Pravachol revenues in 2004 due to the loss of patent exclusivity in Europe and an increasingly competitive U.S. landscape could prompt Bristol-Myers Squibb to intensify efforts to gain nonprescription status for the drug in both markets